ASX: PLS

Amaero Limited (ASX:3DA)

Amaero Limited

ASX: 3DA

Amaero Ltd. engages in manufacturing of large format complex components in metal using laser-based additive manufacturing processes. The company was founded in 2013 and is headquartered in McDonald, TN.


Stock Performance Profile:

(Source: TradingView) One-Year Performance Profile of 3DA on a DTF compared to ASX200 (XJO).

Financial Snapshot (2021-2025):

(Data Source: TradingView. Graphic Source: Pristine Gaze)

  • Revenue top line was subdued from $0.5 million in 2021 to $0.46 million 2024 reflecting the pre‑commercial phase and customer qualification period. FY2025 inflected to $3.8 million as powder sales and PM‑HIP orders scaled, aided by commissioning of a second EIGA atomizer and initial commercialization progress.
  • Cash trended from about $11.5 million (FY2021) down to $8.8 million (FY2023) before rebuilding to $12.0 million (FY2024) and $19.2 million (FY2025), providing runway for execution and working capital as commercial volumes ramp. Management attributes the stronger FY2025 cash position to capital initiatives and operating momentum, alongside a five‑year exclusive powder supply agreement with Velo3D that underpins forward demand visibility.

Relative Strength Index (RSI) Analysis:

Hourly-Time Frame (HTF)-

(Graphic Source: TradingView)

3DA’s hourly RSI is lifting through the 47.65 zone toward 50, pointing to steady improvement as sellers lose control and dip‑buyers step in. A firm close above 55 would confirm momentum rotation and set up a constructive base, with shallow pullbacks likely to be supported rather than sold. If the gauge can hold above the midline while price stays stable, a short burst to 60–65 is feasible, aligning with a near‑term rebound setup and a more positive bias for coming sessions.

Daily-Time Frame (DTF)-

(Graphic Source: TradingView)

On the daily chart, RSI recovering into the high‑30s to low‑40s signals easing downside pressure and a return of measured buying interest. This upturn after oversold readings often precedes basing; holding above 40 would strengthen the case for consolidation before a push toward 45–50. A breakout in RSI through 50 alongside tight price ranges would add confirmation of a short‑term reversal, improving risk‑reward for incremental longs while keeping risk controls beneath recent swing lows.

Support and Resistance Analysis:

3DA may see some near‑term noise, but downside looks limited with firm support at $0.245, where recent lows cluster and buyers previously stepped in to defend the trend’s base. Above, the first resistance sits near $0.350; a daily close over this shelf would likely pull price back into the broken range and reduce supply pressure from October’s breakdown zone. The next resistance is at $0.480, which capped rallies during the August peak and marks the upper range; with price near support and two clear targets overhead, risk‑reward skews positive if $0.35 and then $0.48 clear.​

Bollinger Band Analysis:

(Graphic Source: TradingView)

3DA is trading near the lower band around $0.25–$0.29, showing price is stretched on the downside and sellers are losing momentum as candles ride the band less aggressively. The mid‑band (20‑day average) near $0.32 is the first checkpoint; a close above it would signal mean reversion and increase odds of a push toward the upper band near $0.39. Band width has expanded after the recent drop and is starting to steady, which often precedes a pause or bounce if price can base above the lower band.

Analyst Take

Amaero Limited is moving from setup to scale, with demand locked in and capacity funded, giving clearer revenue visibility than typical early‑stage industrials. A multi‑year, exclusive supply partnership with a leading U.S. printer OEM underpins repeat powder volumes and embeds Amaero’s materials into customer workflows, strengthening switching costs. Recent financing and export‑credit support fully cover the current capex program, lowering execution risk as additional atomisers come online and PM‑HIP volumes build. With early FY26 coverage identified and operations aligned to U.S. re‑shoring in defence, space, and aviation, Amaero offers a de‑risked path to step‑change growth and operating leverage into FY27.

As per Pristine Gaze, you may consider a “Buy” on “Amaero Limited” at the closing price of “$0.285” (As of 22 October 2025).

*All currency figures are in Australian Dollars unless stated otherwise.

*All data sourced from company reports and TradingView.

Disclaimer

The reports provided by Pristine Gaze are designed to deliver general financial insights, including stock and sector market analysis and investment commentary. These reports aim to support informed decision-making but are strictly intended for informational purposes. They do not constitute personalized financial advice and should not be relied upon as such. The information provided does not take into account individual investment objectives, financial circumstances, or specific needs.

General Advice Warning: The insights and recommendations offered in Pristine Gaze reports are of a general nature and are not tailored to any individual investor’s circumstances. Investment decisions are highly personal and depend on many factors, including but not limited to financial goals, risk tolerance, and current financial standing. We strongly advise consulting a qualified financial advisor who can evaluate your unique situation and provide professional guidance tailored to your needs before acting on any information contained in these reports.

Past Performance: Historical data, including past performance metrics of securities or markets mentioned in these reports, should not be regarded as an accurate indicator of future results. The financial markets are subject to significant variability, and past success does not guarantee similar outcomes in the future. It is essential to recognize that external factors, including but not limited to economic conditions, regulatory changes, and market dynamics, can greatly influence future performance and results.

Forward-Looking Statements: Certain projections and forecasts presented in Pristine Gaze reports may include forward-looking statements based on assumptions and expectations about future market conditions. These statements are speculative and inherently uncertain, as they depend on variables that may not materialize as anticipated. Factors such as economic conditions, market trends, policy changes, and unforeseen events can significantly impact these projections. Investors should approach forward-looking statements with caution and recognize the associated risks.

Data Accuracy: All financial data, metrics, and projections contained in our reports are derived from publicly available company filings, credible industry reports, and verified sources. While Pristine Gaze endeavors to ensure the accuracy, timeliness, and reliability of the information provided, we cannot guarantee its completeness or precision. Market conditions and company policies may evolve, leading to changes in the relevance of the data presented. The content of our reports may be updated or modified without prior notice.

Technical Analysis: Reports may include discussions of technical indicators, such as Relative Strength Index (RSI), Bollinger Bands, or moving averages. These indicators are tools used to analyze market trends but are inherently speculative and subject to interpretation. They do not provide definitive predictions about future price movements and should not be relied upon as sole determinants of investment decisions. Investors should combine technical analysis with other forms of research and risk assessment.

Dividend Yield: References to dividend payments or yields are based on historical data and the current financial policies of the companies discussed. Dividends are not guaranteed and may fluctuate depending on the financial performance of the company, market conditions, and regulatory requirements. Investors should consider these variables and the potential for dividend changes when evaluating dividend-paying securities.

Liability Disclaimer: Pristine Gaze, along with its directors, employees, associates, and affiliates, assumes no responsibility or liability for any losses or damages incurred due to reliance on the information or recommendations contained in our reports. This disclaimer applies to all forms of losses, including but not limited to direct, indirect, incidental, or consequential losses. Investors are hereby advised to conduct their independent research and seek professional advice before making investment decisions.

Third-Party Data and Links: some reports may reference external data, include hyperlinks to third-party websites, or incorporate information from other sources. While we aim to use credible and reliable references, Pristine Gaze does not endorse or take responsibility for the accuracy or reliability of external content. Users are advised to evaluate third-party information critically and acknowledge the risks of using such data.

Intellectual Property: All content within Pristine Gaze reports, including but not limited to text, graphics, designs, methodologies, and analyses, is the exclusive intellectual property of Pristine Gaze Pty Ltd. This content is protected under Australian and international copyright and trademark laws. Unauthorized reproduction, modification, or distribution of any part of the content without prior written consent from Pristine Gaze is strictly prohibited. Legal action may be pursued in the case of infringement.

Terms and Policies: For additional information regarding the terms and conditions of our services, our approach to data privacy, and the scope of our financial advice, please refer to our Terms and Conditions, Privacy Policy, and Financial Services Guide, which are available on our official website.

ASX: NXT

Pengana Capital Group Limited (ASX: PCG)

Pengana Capital Group Limited

ASX: PCG

Pengana Capital Group Ltd. engages in the diversified funds management business. The firm investment objective is to offer investment funds to high net worth and retail investors. Its products include Pengana Global Private Credit Trust and TermPlus. The company was founded by Russel Pillemer and Malcolm Turnbull on March 3, 1993 and is headquartered in Sydney, Australia.


Stock Performance Profile:

(Source: TradingView) One-Year Performance Profile of PCG on a DTF compared to ASX200 (XJO).

Financial Snapshot (2021-2025):

(Data Source: TradingView. Graphic Source: Pristine Gaze)

  • Revenue trend: Revenue fell from about $76 million in 2022 to $38 million in 2024 as markets softened and performance fees moderated, then recovered to $58.39 million in 2025 as product mix shifted toward recurring private credit and specialist strategies and distribution initiatives improved flows.
  • Net margin trend: Net margin rose from 55.37% in 2021 to 61.2% in 2022, compressed to 37.83% in 2024 on lower performance fees and higher costs, then rebuilt to 50.05% in 2025 as profitability normalised with stronger fund performance and better operating leverage.

Relative Strength Index (RSI) Analysis:

Hourly-Time Frame (HTF)-

(Graphic Source: TradingView)

The RSI on the hourly chart for PCG is showing encouraging signs of recovery, currently positioned at 42.18, reflecting improving buying interest after a period of weakness. The gradual uptick from recent lower levels suggests that momentum is starting to build. If this positive trend continues and the RSI moves above the 50–55 zone, it could confirm a strengthening bullish sentiment, indicating that the stock may be gearing up for a potential upward move in the near term.

Daily-Time Frame (DTF)-

(Graphic Source: TradingView)

The RSI on the daily time frame is currently around 38.88, indicating a steady recovery from oversold conditions. This upward movement highlights easing bearish momentum and the return of moderate buying interest. The improving RSI trend suggests that the stock may be entering a consolidation phase, often seen before a potential rebound. If this strength continues alongside stable price action, it could mark the beginning of a short-term reversal, supporting a positive outlook for the sessions ahead.

Support and Resistance Analysis:

(Graphic Source: TradingView)

PCG may see some near‑term noise, but downside looks limited with firm support at $0.665, where recent lows and buying interest align. Above, the first resistance sits near $0.72–$0.73; a close over this zone would likely draw price back into the prior range. The next resistance is at $0.810, which capped rallies earlier in the year and marks the range top. With price near support and two clear targets overhead, the risk‑reward is favourable: limited slippage below $0.665 versus meaningful upside if $0.73 and then $0.82 break.

Bollinger Band Analysis:

(Graphic Source: TradingView)

PCG is stabilising near the lower Bollinger Band around $0.66–$0.67 while the 20‑day mid‑band sits near $0.726; price rejecting the lower band and curling toward the mid‑band often precedes a relief move. Bands have widened after a sharp drop and are starting to flatten, suggesting downside momentum is fading and volatility may compress before a mean‑reversion attempt. A daily close back above the mid‑band ($0.726) would confirm improving trend tone and set a path toward the upper band near $0.80.

Analyst Take

Pengana Capital has shown consistent operational and financial improvement, supported by its focus on expanding assets under management and delivering stronger investment performance. The company’s recent profitability turnaround and growing revenue base highlight effective execution of its strategic growth plans. Its disciplined cost management and scalable model strengthen long-term fundamentals, while consistent inflows reflect improving investor confidence. Though a high-risk stock, the short-term scope appears promising as market sentiment improves. Investors should remain attentive to stop-loss levels, yet the company’s sustainable growth approach and robust financial strategy suggest it may evolve into a rewarding mid- to long-term investment opportunity for those seeking exposure to a growing and well-diversified financial services player.

As per Pristine Gaze, you may consider a “Buy” on “Pengana Capital Group Limited” at the closing price of “$0.68” (As of 08 October 2025).

*All currency figures are in Australian Dollars unless stated otherwise.

*All data sourced from company reports and TradingView.

Disclaimer

The reports provided by Pristine Gaze are designed to deliver general financial insights, including stock and sector market analysis and investment commentary. These reports aim to support informed decision-making but are strictly intended for informational purposes. They do not constitute personalized financial advice and should not be relied upon as such. The information provided does not take into account individual investment objectives, financial circumstances, or specific needs.

General Advice Warning: The insights and recommendations offered in Pristine Gaze reports are of a general nature and are not tailored to any individual investor’s circumstances. Investment decisions are highly personal and depend on many factors, including but not limited to financial goals, risk tolerance, and current financial standing. We strongly advise consulting a qualified financial advisor who can evaluate your unique situation and provide professional guidance tailored to your needs before acting on any information contained in these reports.

Past Performance: Historical data, including past performance metrics of securities or markets mentioned in these reports, should not be regarded as an accurate indicator of future results. The financial markets are subject to significant variability, and past success does not guarantee similar outcomes in the future. It is essential to recognize that external factors, including but not limited to economic conditions, regulatory changes, and market dynamics, can greatly influence future performance and results.

Forward-Looking Statements: Certain projections and forecasts presented in Pristine Gaze reports may include forward-looking statements based on assumptions and expectations about future market conditions. These statements are speculative and inherently uncertain, as they depend on variables that may not materialize as anticipated. Factors such as economic conditions, market trends, policy changes, and unforeseen events can significantly impact these projections. Investors should approach forward-looking statements with caution and recognize the associated risks.

Data Accuracy: All financial data, metrics, and projections contained in our reports are derived from publicly available company filings, credible industry reports, and verified sources. While Pristine Gaze endeavors to ensure the accuracy, timeliness, and reliability of the information provided, we cannot guarantee its completeness or precision. Market conditions and company policies may evolve, leading to changes in the relevance of the data presented. The content of our reports may be updated or modified without prior notice.

Technical Analysis: Reports may include discussions of technical indicators, such as Relative Strength Index (RSI), Bollinger Bands, or moving averages. These indicators are tools used to analyze market trends but are inherently speculative and subject to interpretation. They do not provide definitive predictions about future price movements and should not be relied upon as sole determinants of investment decisions. Investors should combine technical analysis with other forms of research and risk assessment.

Dividend Yield: References to dividend payments or yields are based on historical data and the current financial policies of the companies discussed. Dividends are not guaranteed and may fluctuate depending on the financial performance of the company, market conditions, and regulatory requirements. Investors should consider these variables and the potential for dividend changes when evaluating dividend-paying securities.

Liability Disclaimer: Pristine Gaze, along with its directors, employees, associates, and affiliates, assumes no responsibility or liability for any losses or damages incurred due to reliance on the information or recommendations contained in our reports. This disclaimer applies to all forms of losses, including but not limited to direct, indirect, incidental, or consequential losses. Investors are hereby advised to conduct their independent research and seek professional advice before making investment decisions.

Third-Party Data and Links: some reports may reference external data, include hyperlinks to third-party websites, or incorporate information from other sources. While we aim to use credible and reliable references, Pristine Gaze does not endorse or take responsibility for the accuracy or reliability of external content. Users are advised to evaluate third-party information critically and acknowledge the risks of using such data.

Intellectual Property: All content within Pristine Gaze reports, including but not limited to text, graphics, designs, methodologies, and analyses, is the exclusive intellectual property of Pristine Gaze Pty Ltd. This content is protected under Australian and international copyright and trademark laws. Unauthorized reproduction, modification, or distribution of any part of the content without prior written consent from Pristine Gaze is strictly prohibited. Legal action may be pursued in the case of infringement.

Terms and Policies: For additional information regarding the terms and conditions of our services, our approach to data privacy, and the scope of our financial advice, please refer to our Terms and Conditions, Privacy Policy, and Financial Services Guide, which are available on our official website.

ASX: TLX

HighCom Limited (ASX:HCL)

HighCom Limited

ASX: HCL

HighCom Ltd. provides security services. It offers security products to protect and sustain the defence forces, police forces and other government agencies. The firm operates through the following business units: Lightweight Composites; Explosive Ordnance Disposal; Forensics; Small Unmanned Aerial Systems; and Tactical and Protective Solutions. The company was founded on February 13, 1978 and is headquartered in Canberra, Australia.


Stock Performance Profile:

(Source: TradingView) One-Year Performance Profile of HCL on a DTF compared to ASX200 (XJO).

Financial Snapshot (2021-2025):

(Data Source: TradingView. Graphic Source: Pristine Gaze)

Financial Performance: Over 2021–2025, revenue rose from $28.2 million to $48.1 million, peaking in 2023 at $89.4 million before moderating in 2024–2025. Net income followed a volatile path, with profits in 2022–2023 offset by losses in 2021 and a steep setback in 2024. FY25 shows partial recovery with a smaller net loss, reflecting order timing and restructuring initiatives.

Cash from Operating Activities: CFO has been highly volatile, swinging from $26.0 million in 2022 to -$26.3 million in 2023. FY24–FY25 show positive though modest cash inflows, supported by management’s focus on inventory discipline and stabilising working capital.

Relative Strength Index (RSI) Analysis:

Hourly-Time Frame (HTF)-

(Graphic Source: TradingView)

In the hourly chart, HCL’s RSI currently stands at 40.43, slightly below neutral. This indicates the stock has recovered from oversold conditions but has not yet entered a strong bullish zone above 50. The short-term moving average is near 42.16, which is acting as a soft ceiling for momentum. This setup highlights early buying interest and potential for a short-term reversal if RSI continues higher. Sustained movement above 50 would confirm stronger recovery momentum.

Daily-Time Frame (DTF)-

(Graphic Source: TradingView)

On the daily chart, HCL’s RSI sits at 38.10. This places the stock near levels where past rebounds have historically started, showing potential for renewed upward momentum if buying pressure increases. Previous recoveries from similar RSI zones have often led to multi-week rallies. A close above the daily SMA would strengthen the case for a medium-term trend reversal, as it would confirm stabilising sentiment and improving demand for the stock.

Support and Resistance Analysis:

(Graphic Source: TradingView)

HCL is currently trading near a key support level around $0.285, which has repeatedly acted as a base for recent price movements. A stronger support lies at $0.170, representing a more established long-term floor. On the upside, the nearest resistance is around $0.350, and a breakout above this level could trigger momentum toward the next major resistance near $0.52. The wide gap between support and resistance suggests significant upside potential if reversal signals are confirmed, though downside risks remain if support fails.

Bollinger Band Analysis:

(Graphic Source: TradingView)

The Bollinger Bands show the 20-day SMA near $0.312, with the upper band at $0.374 and the lower band at $0.250. HCL is now chasing its 20SMA marking a chance for rally. The bands are narrowing, which signals volatility compression — a common precursor to larger price moves. The flattening of the lower band near 0.25 indicates limited further downside in the short term. A decisive move back above the SMA would support a bullish reversal.

Analyst Take

HighCom is transitioning into a more resilient growth phase, underpinned by a strong pipeline of defense and security contracts. The company’s product innovation, including the XTclave technology and expansion of its armour solutions, positions it well in markets demanding advanced protective equipment. Management’s transformation program is beginning to show early traction, with operational efficiency and inventory discipline improving cash conversion. A diversified order book across geographies provides visibility and reduces reliance on single markets. Importantly, industry tailwinds from heightened defense spending globally add momentum to revenue opportunities. While near-term earnings remain sensitive to contract timing, the long-term strategy of scaling production and leveraging proprietary technology supports stronger profitability. For investors, this combination of innovation, expanding demand, and operational discipline makes HighCom an attractive medium-term growth opportunity.

As per Pristine Gaze, you may consider a “Buy” on “HighCom Limited” at the closing price of “$0.285” (As of 24 September 2025).

*All currency figures are in Australian Dollars unless stated otherwise.

*All data sourced from company reports and TradingView.

Disclaimer

The reports provided by Pristine Gaze are designed to deliver general financial insights, including stock and sector market analysis and investment commentary. These reports aim to support informed decision-making but are strictly intended for informational purposes. They do not constitute personalized financial advice and should not be relied upon as such. The information provided does not take into account individual investment objectives, financial circumstances, or specific needs.

General Advice Warning: The insights and recommendations offered in Pristine Gaze reports are of a general nature and are not tailored to any individual investor’s circumstances. Investment decisions are highly personal and depend on many factors, including but not limited to financial goals, risk tolerance, and current financial standing. We strongly advise consulting a qualified financial advisor who can evaluate your unique situation and provide professional guidance tailored to your needs before acting on any information contained in these reports.

Past Performance: Historical data, including past performance metrics of securities or markets mentioned in these reports, should not be regarded as an accurate indicator of future results. The financial markets are subject to significant variability, and past success does not guarantee similar outcomes in the future. It is essential to recognize that external factors, including but not limited to economic conditions, regulatory changes, and market dynamics, can greatly influence future performance and results.

Forward-Looking Statements: Certain projections and forecasts presented in Pristine Gaze reports may include forward-looking statements based on assumptions and expectations about future market conditions. These statements are speculative and inherently uncertain, as they depend on variables that may not materialize as anticipated. Factors such as economic conditions, market trends, policy changes, and unforeseen events can significantly impact these projections. Investors should approach forward-looking statements with caution and recognize the associated risks.

Data Accuracy: All financial data, metrics, and projections contained in our reports are derived from publicly available company filings, credible industry reports, and verified sources. While Pristine Gaze endeavors to ensure the accuracy, timeliness, and reliability of the information provided, we cannot guarantee its completeness or precision. Market conditions and company policies may evolve, leading to changes in the relevance of the data presented. The content of our reports may be updated or modified without prior notice.

Technical Analysis: Reports may include discussions of technical indicators, such as Relative Strength Index (RSI), Bollinger Bands, or moving averages. These indicators are tools used to analyze market trends but are inherently speculative and subject to interpretation. They do not provide definitive predictions about future price movements and should not be relied upon as sole determinants of investment decisions. Investors should combine technical analysis with other forms of research and risk assessment.

Dividend Yield: References to dividend payments or yields are based on historical data and the current financial policies of the companies discussed. Dividends are not guaranteed and may fluctuate depending on the financial performance of the company, market conditions, and regulatory requirements. Investors should consider these variables and the potential for dividend changes when evaluating dividend-paying securities.

Liability Disclaimer: Pristine Gaze, along with its directors, employees, associates, and affiliates, assumes no responsibility or liability for any losses or damages incurred due to reliance on the information or recommendations contained in our reports. This disclaimer applies to all forms of losses, including but not limited to direct, indirect, incidental, or consequential losses. Investors are hereby advised to conduct their independent research and seek professional advice before making investment decisions.

Third-Party Data and Links: some reports may reference external data, include hyperlinks to third-party websites, or incorporate information from other sources. While we aim to use credible and reliable references, Pristine Gaze does not endorse or take responsibility for the accuracy or reliability of external content. Users are advised to evaluate third-party information critically and acknowledge the risks of using such data.

Intellectual Property: All content within Pristine Gaze reports, including but not limited to text, graphics, designs, methodologies, and analyses, is the exclusive intellectual property of Pristine Gaze Pty Ltd. This content is protected under Australian and international copyright and trademark laws. Unauthorized reproduction, modification, or distribution of any part of the content without prior written consent from Pristine Gaze is strictly prohibited. Legal action may be pursued in the case of infringement.

Terms and Policies: For additional information regarding the terms and conditions of our services, our approach to data privacy, and the scope of our financial advice, please refer to our Terms and Conditions, Privacy Policy, and Financial Services Guide, which are available on our official website.

Aussie Broadband

Telix Pharmaceuticals Limited (ASX: TLX)

Telix Pharmaceuticals Limited

ASX: TLX

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.


Stock Performance Profile:

(Source: TradingView) One-Year Performance Profile of TLX on a DTF compared to ASX200 (XJO).

Financial Snapshot (2020-2024):

(Data Source: TradingView. Graphic Source: Pristine Gaze)

Over the past five years, Telix Pharmaceuticals has delivered a strong and improving financial trajectory:

  • Telix has experienced significant topline growth, with revenue climbing from $5.21 million in 2020 to $783.21 million in 2024. Net income turned positive in 2024 to $49.92 million with a 55.85% increase YOY, marking its consecutive second year of profitability—driven by global uptake of Illuccix and improved operating leverage.
  • Net margin improved from a deep negative (–1060% in 2021) to a healthy 6.37% in 2024. This shift underscores Telix’s successful transition from clinical-stage development to sustainable commercial operations.
  • Gross margin rose from –391.85% in 2021 to 65.16% in 2024, reflecting pricing strength, manufacturing scale, and better cost absorption across products.
  • Operating cash flow turned positive in 2023 ($23.88 million) and further strengthened to $43.03 million in 2024, demonstrating the company’s ability to generate cash from its core operations and improved financial discipline.

Relative Strength Index (RSI) Analysis:

Hourly Time-Frame (HTF) –

(Graphic Source: TradingView)

The RSI on the hourly time frame (HTF) has recently rebounded from oversold territory near the 29.5 level, indicating a shift in market sentiment. This slow but steady upward momentum now points toward the threshold of bullish zones, typically around the 50–60 mark, which often precedes stronger upward price action.

Daily Time-Frame (DTF) –

(Graphic Source: TradingView)

The security’s RSI is currently positioned at 33 on the daily time frame (DTF), hovering just above oversold territory. This level, coupled with signs of waning selling pressure, suggests that the downside momentum is tapering off. Such conditions often precede a potential trend reversal, particularly when accompanied by stabilizing price action or supportive volume patterns. While confirmation is still needed, the current RSI behavior points toward the early stages of a base formation, encouraging a cautiously optimistic outlook for a short-term rebound.

Support & Resistance Analysis:

(Graphic Source: TradingView)

While the security may face some residual downside correction, the risk appears constrained, with technical support anticipated near the $13.51 level. This support zone may act as a stabilizing base in the short term. Additionally, the next major resistance level is situated around $18.95, with further resistance around $25.75, indicating a relatively wide price gap. This dynamic establishes a favourable risk-reward profile for investors, as the potential upside notably outweighs the limited downside risk at current price levels of $14.42.

Bollinger Bands Analysis:

(Graphic Source: TradingView)

The security has recently breached its lower Bollinger Bands on the daily timeframe chart, indicating the potential for a near-term trend reversal. This technical signal suggests a possible retracement toward its short-term simple moving average (SMA), and the stock has now begun its recovery. Should this recovery continue, there remains considerable scope for additional upside momentum, with the upper Bollinger Band serving as a potential short-term target.

Analyst Take

Telix Pharmaceuticals has matured into a leading force in radiopharmaceuticals, delivering strong half-year momentum with revenue growth driven by Illuccix and the successful U.S. launch of Gozellix. The company is now leveraging its theranostics expertise to expand into prostate, renal, and brain cancer treatments through late-stage programs such as ProstACT and TLX250. With new commercial rollouts, including Zircaix and Pixclara, Telix is broadening its oncology footprint while deepening physician adoption. Manufacturing capacity expansions in Brussels and Indianapolis provide critical scale to meet anticipated demand. Strategic use of proprietary biomarkers and AI-supported imaging enhances clinical precision, strengthening competitive positioning. Despite inherent biotech risks, Telix’s diversified pipeline, proven ability to commercialise innovation, and reaffirmed guidance of $770–800 million for FY2025 make it a compelling investment case with robust long-term growth potential.

As per Pristine Gaze, you may consider a “Buy” on “Telix Pharmaceuticals Limited” at the closing price of “$14.42” (As of 10 September 2025).

*All currency figures are in Australian Dollars unless stated otherwise.

*All data sourced from Company Reports and TradingView.

Disclaimer

The reports provided by Pristine Gaze are designed to deliver general financial insights, including stock and sector market analysis and investment commentary. These reports aim to support informed decision-making but are strictly intended for informational purposes. They do not constitute personalized financial advice and should not be relied upon as such. The information provided does not take into account individual investment objectives, financial circumstances, or specific needs.

General Advice Warning: The insights and recommendations offered in Pristine Gaze reports are of a general nature and are not tailored to any individual investor’s circumstances. Investment decisions are highly personal and depend on many factors, including but not limited to financial goals, risk tolerance, and current financial standing. We strongly advise consulting a qualified financial advisor who can evaluate your unique situation and provide professional guidance tailored to your needs before acting on any information contained in these reports.

Past Performance: Historical data, including past performance metrics of securities or markets mentioned in these reports, should not be regarded as an accurate indicator of future results. The financial markets are subject to significant variability, and past success does not guarantee similar outcomes in the future. It is essential to recognize that external factors, including but not limited to economic conditions, regulatory changes, and market dynamics, can greatly influence future performance and results.

Forward-Looking Statements: Certain projections and forecasts presented in Pristine Gaze reports may include forward-looking statements based on assumptions and expectations about future market conditions. These statements are speculative and inherently uncertain, as they depend on variables that may not materialize as anticipated. Factors such as economic conditions, market trends, policy changes, and unforeseen events can significantly impact these projections. Investors should approach forward-looking statements with caution and recognize the associated risks.

Data Accuracy: All financial data, metrics, and projections contained in our reports are derived from publicly available company filings, credible industry reports, and verified sources. While Pristine Gaze endeavors to ensure the accuracy, timeliness, and reliability of the information provided, we cannot guarantee its completeness or precision. Market conditions and company policies may evolve, leading to changes in the relevance of the data presented. The content of our reports may be updated or modified without prior notice.

Technical Analysis: Reports may include discussions of technical indicators, such as Relative Strength Index (RSI), Bollinger Bands, or moving averages. These indicators are tools used to analyze market trends but are inherently speculative and subject to interpretation. They do not provide definitive predictions about future price movements and should not be relied upon as sole determinants of investment decisions. Investors should combine technical analysis with other forms of research and risk assessment.

Dividend Yield: References to dividend payments or yields are based on historical data and the current financial policies of the companies discussed. Dividends are not guaranteed and may fluctuate depending on the financial performance of the company, market conditions, and regulatory requirements. Investors should consider these variables and the potential for dividend changes when evaluating dividend-paying securities.

Liability Disclaimer: Pristine Gaze, along with its directors, employees, associates, and affiliates, assumes no responsibility or liability for any losses or damages incurred due to reliance on the information or recommendations contained in our reports. This disclaimer applies to all forms of losses, including but not limited to direct, indirect, incidental, or consequential losses. Investors are hereby advised to conduct their independent research and seek professional advice before making investment decisions.

Third-Party Data and Links: some reports may reference external data, include hyperlinks to third-party websites, or incorporate information from other sources. While we aim to use credible and reliable references, Pristine Gaze does not endorse or take responsibility for the accuracy or reliability of external content. Users are advised to evaluate third-party information critically and acknowledge the risks of using such data.

Intellectual Property: All content within Pristine Gaze reports, including but not limited to text, graphics, designs, methodologies, and analyses, is the exclusive intellectual property of Pristine Gaze Pty Ltd. This content is protected under Australian and international copyright and trademark laws. Unauthorized reproduction, modification, or distribution of any part of the content without prior written consent from Pristine Gaze is strictly prohibited. Legal action may be pursued in the case of infringement.

Terms and Policies: For additional information regarding the terms and conditions of our services, our approach to data privacy, and the scope of our financial advice, please refer to our Terms and Conditions, Privacy Policy, and Financial Services Guide, which are available on our official website.

Rare Earth Stocks

Calix Limited (ASX: CXL)

Calix Limited

ASX: CXL

Calix Ltd. engages in the development of patent-protected, platform technology that produces new materials and processes to solve global challenges. The company products include ACTI-Mag, AQUA-Cal+, PROTECTA-Mag, and BOOSTER-Mag. It operates through the following segments: LEILAC, US, and Australian & SE Asian segments. The LEILAC segment is in Europe with a small US subsidiary who collectively are the CO2 mitigation business line. The US segment is the US section of the water business line. The company was founded by Mark Sceats and Conner Horley on November 13, 2005 and is headquartered in Pymble, Australia.

Stock Performance Profile:

(Source: TradingView) One-Year Performance Profile of CXL on a DTF compared to ASX200 (XJO).

Financial Snapshot (2021-2025):

(Data Source: TradingView. Graphic Source: Pristine Gaze)

  • Calix’s revenue was largely flat between FY21–FY23 (~$19 million), before accelerating to $24.2 million in FY24 and $28.2 million in FY25, supported by Magnesia growth and Leilac engineering services. Net income remained negative across the period, with losses deepening to $25.3 million in FY24 due to higher R&D and project costs, before narrowing to $19.2 million in FY25, reflecting early benefits of revenue diversification and cost discipline.
  • Margins fluctuated sharply, turning negative from FY23 (–12.9%) to FY25 (–2.4%). Despite this, FY24 product and services gross margin improved to 43% (vs 33% in FY23), indicating underlying strength in core operations even as group margins were weighed down by project development costs.

Relative Strength Index (RSI) Analysis:

Hourly Time-Frame (HTF) –

(Graphic Source: TradingView)

In the hourly time frame (HTF) evaluations, the security’s Relative Strength Index (RSI) currently registers at 45.41, approaching bullish zones near the 50 level. This configuration reflects positive buying momentum over very short-term periods, while also serving as a constructive signal for broader trend reversion. The HTF further indicates a recent retracement from oversold conditions, evidencing an active recovery in the short term. Such RSI patterns, observed in ASX-listed equities, often precede mean-reversion phases, particularly when complemented by underlying financial growth metrics and historical momentum data.

Daily Time-Frame (DTF) –

(Graphic Source: TradingView)

In daily time frame (DTF) observations, the security displays a noteworthy pattern characterized by historical recoveries in buying momentum and market sentiment near RSI levels of 36, proximate to the current reading of 42. This proximity underscores potential for renewed upward momentum. Furthermore, past instances reveal a strong correlation between price action and buying momentum during recovery phases, reinforcing expectations of similar behavior based on empirical precedents in the security’s performance data.

Support & Resistance Analysis:

(Graphic Source: TradingView)

The security is currently nearing key support levels at approximately $0.38, exhibiting patterns akin to those in its Relative Strength Index (RSI), which allow for limited additional downside. The nearest resistance stands at $0.62, positioned at a considerable distance, thereby indicating substantial upside room upon reversal. Subsequent price targets extend to around $0.90, which, while entailing notable risks including market volatility, further bolsters the potential for meaningful gains.

Bollinger Bands Analysis:

(Graphic Source: TradingView)

The security’s lower Bollinger Band is exhibiting sustained upward movement, contributing to a progressive narrowing of the overall price range. This development, combined with anticipated limited price declines, suggests an imminent potential breach of the lower band. Such a breach typically signals a reversal opportunity, as it coincides with the security’s price approaching its simple moving average (SMA). Historical observations of Bollinger Band contractions in momentum-driven assets indicate heightened volatility compression, often preceding directional shifts when aligned with underlying trend indicators.

Analyst Take:

Calix Limited has shown meaningful progress in building a platform for long-term growth, underpinned by its innovative decarbonisation and sustainable processing technologies. Revenue has gained momentum in recent years, supported by strong contributions from Magnesia operations and growing Leilac engineering services. Strategic partnerships, government grants, and targeted equity raises reinforce both external confidence and financial flexibility to advance key demonstration projects. Although short-term earnings are limited by elevated research and development expenditures and operational scaling expenses, enhancements in core segment margins underscore emerging efficiency gains. Through dedicated efforts in commercialisation and broadening international deployments, Calix stands well-placed to capitalize on escalating market needs for environmentally sustainable solutions.

As per Pristine Gaze, you may consider a “Buy” on “Calix Limited” at the closing price of “$0.425” (As of 27 August 2025).

*All currency figures are in Australian Dollars unless stated otherwise.

*All data sourced from company reports and TradingView.

Disclaimer

The reports provided by Pristine Gaze are designed to deliver general financial insights, including stock and sector market analysis and investment commentary. These reports aim to support informed decision-making but are strictly intended for informational purposes. They do not constitute personalized financial advice and should not be relied upon as such. The information provided does not take into account individual investment objectives, financial circumstances, or specific needs.

General Advice Warning: The insights and recommendations offered in Pristine Gaze reports are of a general nature and are not tailored to any individual investor’s circumstances. Investment decisions are highly personal and depend on many factors, including but not limited to financial goals, risk tolerance, and current financial standing. We strongly advise consulting a qualified financial advisor who can evaluate your unique situation and provide professional guidance tailored to your needs before acting on any information contained in these reports.

Past Performance: Historical data, including past performance metrics of securities or markets mentioned in these reports, should not be regarded as an accurate indicator of future results. The financial markets are subject to significant variability, and past success does not guarantee similar outcomes in the future. It is essential to recognize that external factors, including but not limited to economic conditions, regulatory changes, and market dynamics, can greatly influence future performance and results.

Forward-Looking Statements: Certain projections and forecasts presented in Pristine Gaze reports may include forward-looking statements based on assumptions and expectations about future market conditions. These statements are speculative and inherently uncertain, as they depend on variables that may not materialize as anticipated. Factors such as economic conditions, market trends, policy changes, and unforeseen events can significantly impact these projections. Investors should approach forward-looking statements with caution and recognize the associated risks.

Data Accuracy: All financial data, metrics, and projections contained in our reports are derived from publicly available company filings, credible industry reports, and verified sources. While Pristine Gaze endeavors to ensure the accuracy, timeliness, and reliability of the information provided, we cannot guarantee its completeness or precision. Market conditions and company policies may evolve, leading to changes in the relevance of the data presented. The content of our reports may be updated or modified without prior notice.

Technical Analysis: Reports may include discussions of technical indicators, such as Relative Strength Index (RSI), Bollinger Bands, or moving averages. These indicators are tools used to analyze market trends but are inherently speculative and subject to interpretation. They do not provide definitive predictions about future price movements and should not be relied upon as sole determinants of investment decisions. Investors should combine technical analysis with other forms of research and risk assessment.

Dividend Yield: References to dividend payments or yields are based on historical data and the current financial policies of the companies discussed. Dividends are not guaranteed and may fluctuate depending on the financial performance of the company, market conditions, and regulatory requirements. Investors should consider these variables and the potential for dividend changes when evaluating dividend-paying securities.

Liability Disclaimer: Pristine Gaze, along with its directors, employees, associates, and affiliates, assumes no responsibility or liability for any losses or damages incurred due to reliance on the information or recommendations contained in our reports. This disclaimer applies to all forms of losses, including but not limited to direct, indirect, incidental, or consequential losses. Investors are hereby advised to conduct their independent research and seek professional advice before making investment decisions.

Third-Party Data and Links: some reports may reference external data, include hyperlinks to third-party websites, or incorporate information from other sources. While we aim to use credible and reliable references, Pristine Gaze does not endorse or take responsibility for the accuracy or reliability of external content. Users are advised to evaluate third-party information critically and acknowledge the risks of using such data.

Intellectual Property: All content within Pristine Gaze reports, including but not limited to text, graphics, designs, methodologies, and analyses, is the exclusive intellectual property of Pristine Gaze Pty Ltd. This content is protected under Australian and international copyright and trademark laws. Unauthorized reproduction, modification, or distribution of any part of the content without prior written consent from Pristine Gaze is strictly prohibited. Legal action may be pursued in the case of infringement.

Terms and Policies: For additional information regarding the terms and conditions of our services, our approach to data privacy, and the scope of our financial advice, please refer to our Terms and Conditions, Privacy Policy, and Financial Services Guide, which are available on our official website.

Star Entertainment Group

QBE Insurance Group Limited (ASX: QBE)

QBE Insurance Group Limited

ASX: QBE

QBE Insurance Group Ltd. engages in providing underwriting general insurance and reinsurance risks. It operates through the following geographical segments: North America, International, Australia Pacific, and Corporate and Other. The North America segment writes general insurance, reinsurance, and crop business in the United States. The International segment offers general insurance business in the United Kingdom, Europ, and Canada. The Australia Pacific segment underwrites general insurance risks throughout Australia, New Zealand, and the Pacific region. The Corporate and Other segment is involved in non-operating holding companies that do not form part pf the group’s insurance operations. The company was founded in October 1888 is headquartered in Sydney, Australia.

Stock Performance Profile:

(Source: TradingView) One-Year Performance Profile of QBE on a DTF compared to ASX200 (XJO).

Financial Snapshot (2020-2024):

(Data Source: TradingView. Graphic Source: Pristine Gaze)

Over the past five years, QBE Insurance Group has delivered a strong and improving financial trajectory:

  • Revenue has expanded consistently from $17.68 billion in 2020 to $34.6 billion in 2024, CAGR 18.28%, driven by disciplined premium rate increases, targeted business expansion, and portfolio optimisation. Net income demonstrates a remarkable turnaround—from a $2.2 billion loss in 2020 to $2.7 billion profit in 2024—reflecting improved underwriting discipline, lower catastrophe costs, and stronger investment returns.
  • Operating margins have shifted from a negative -5.28% in 2020 to 11.59% in 2024, with steady year-on-year gains since 2022, showcasing QBE’s enhanced efficiency and profitability. This margin expansion aligns with the improved combined operating ratio and stable claims performance, highlighting the resilience of its core insurance operations.

Relative Strength Index (RSI) Analysis:

Hourly Time-Frame (HTF) –

(Graphic Source: TradingView)

The security’s RSI on the HTF reflects a notable improvement in buying activity and momentum. Notably, the chart displays a bullish RSI divergence — while the RSI has recovered from oversold levels near 22 to its current reading around 37, the price continues to trade slightly lower. This divergence suggests a potential short-term upside for investors as momentum strengthens despite price weakness.

Daily Time-Frame (DTF) –

(Graphic Source: TradingView)

The security’s RSI on the DTF has recently rebounded from oversold territory near the 30 level—an event last seen around April, which was followed by a significant rally. The current rebound mirrors that earlier pattern, with the RSI now rising to 35, signaling improving buying sentiment.

Support & Resistance Analysis:

(Graphic Source: TradingView)

The security has consolidated near a key support level on the DTF around $21, with the nearest resistance positioned significantly higher at $22.48, indicating notable short-term upside potential. Strong underlying fundamentals further support the prospect of the security advancing toward higher resistance levels at $23.23 and $24.

Bollinger Bands Analysis:

(Graphic Source: TradingView)

QBE has breached its lower Bollinger Band, a technical signal that often points to a potential rebound. Additionally, the wide gap between the upper and lower bands suggests elevated volatility, which can precede significant price swings. This setup increases the probability of an upward move, with the stock potentially gravitating toward its simple moving average near $22.58.

Analyst Take:

QBE Insurance Group has showcased a compelling blend of operational resilience and financial strength, marking consistent gains in underwriting performance, capital position, and shareholder returns. The latest results reflect disciplined portfolio optimisation, a robust combined operating ratio of 93.1%, and steady premium growth despite selective market exits. Elevated interest rates have underpinned record investment income, while the Board’s $0.63 final dividend brings the full-year payout to an attractive yield. With its trailing twelve-month P/E ratio at an all-time low of 10.83, valuation appears compelling against historical norms. Technically, an RSI divergence on the hourly chart hints at potential upside momentum, aligning with the company’s solid fundamentals. QBE’s balance of stable returns, prudent risk management, and strategic positioning in resilient insurance segments makes it a notable candidate for investors seeking both income and value. The current setup offers an enticing mix of dividend strength and near-term technical support.

As per Pristine Gaze, you may consider a “Buy” on “QBE Insurance Group Limited” at the closing price of “$21.12” (As of 13 August 2025).

*All currency figures are in Australian Dollars unless stated otherwise.

*All data sourced from company reports and TradingView.

Disclaimer

The reports provided by Pristine Gaze are designed to deliver general financial insights, including stock and sector market analysis and investment commentary. These reports aim to support informed decision-making but are strictly intended for informational purposes. They do not constitute personalized financial advice and should not be relied upon as such. The information provided does not take into account individual investment objectives, financial circumstances, or specific needs.

General Advice Warning: The insights and recommendations offered in Pristine Gaze reports are of a general nature and are not tailored to any individual investor’s circumstances. Investment decisions are highly personal and depend on many factors, including but not limited to financial goals, risk tolerance, and current financial standing. We strongly advise consulting a qualified financial advisor who can evaluate your unique situation and provide professional guidance tailored to your needs before acting on any information contained in these reports.

Past Performance: Historical data, including past performance metrics of securities or markets mentioned in these reports, should not be regarded as an accurate indicator of future results. The financial markets are subject to significant variability, and past success does not guarantee similar outcomes in the future. It is essential to recognize that external factors, including but not limited to economic conditions, regulatory changes, and market dynamics, can greatly influence future performance and results.

Forward-Looking Statements: Certain projections and forecasts presented in Pristine Gaze reports may include forward-looking statements based on assumptions and expectations about future market conditions. These statements are speculative and inherently uncertain, as they depend on variables that may not materialize as anticipated. Factors such as economic conditions, market trends, policy changes, and unforeseen events can significantly impact these projections. Investors should approach forward-looking statements with caution and recognize the associated risks.

Data Accuracy: All financial data, metrics, and projections contained in our reports are derived from publicly available company filings, credible industry reports, and verified sources. While Pristine Gaze endeavors to ensure the accuracy, timeliness, and reliability of the information provided, we cannot guarantee its completeness or precision. Market conditions and company policies may evolve, leading to changes in the relevance of the data presented. The content of our reports may be updated or modified without prior notice.

Technical Analysis: Reports may include discussions of technical indicators, such as Relative Strength Index (RSI), Bollinger Bands, or moving averages. These indicators are tools used to analyze market trends but are inherently speculative and subject to interpretation. They do not provide definitive predictions about future price movements and should not be relied upon as sole determinants of investment decisions. Investors should combine technical analysis with other forms of research and risk assessment.

Dividend Yield: References to dividend payments or yields are based on historical data and the current financial policies of the companies discussed. Dividends are not guaranteed and may fluctuate depending on the financial performance of the company, market conditions, and regulatory requirements. Investors should consider these variables and the potential for dividend changes when evaluating dividend-paying securities.

Liability Disclaimer: Pristine Gaze, along with its directors, employees, associates, and affiliates, assumes no responsibility or liability for any losses or damages incurred due to reliance on the information or recommendations contained in our reports. This disclaimer applies to all forms of losses, including but not limited to direct, indirect, incidental, or consequential losses. Investors are hereby advised to conduct their independent research and seek professional advice before making investment decisions.

Third-Party Data and Links: some reports may reference external data, include hyperlinks to third-party websites, or incorporate information from other sources. While we aim to use credible and reliable references, Pristine Gaze does not endorse or take responsibility for the accuracy or reliability of external content. Users are advised to evaluate third-party information critically and acknowledge the risks of using such data.

Intellectual Property: All content within Pristine Gaze reports, including but not limited to text, graphics, designs, methodologies, and analyses, is the exclusive intellectual property of Pristine Gaze Pty Ltd. This content is protected under Australian and international copyright and trademark laws. Unauthorized reproduction, modification, or distribution of any part of the content without prior written consent from Pristine Gaze is strictly prohibited. Legal action may be pursued in the case of infringement.

Ava Risk Group Limited (ASX: AVA)

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Ava Risk Group Limited

ASX:
AVA

Ava Risk Group Ltd. provides risk management services and technologies. It operates through the following segments: Detect, Access, and Illuminate. The Detect segment is involved in manufacturing and marketing fiber optic sensing systems for security and condition monitoring for a range of applications including perimeters, pipelines, conveyors, power cables, and data networks. The Access segment focuses on development, manufacture, and supply of high security biometric readers, security access control, and electronic locking products. The Illuminate segment refers to the development and manufacture of illuminators, ANPR cameras, and perimeter detectors. The company was founded on March 29, 1994, and is headquartered in Mulgrave, Australia.

Stock Performance Profile:

(Source: TradingView) One-Year Performance Profile of AVA compared to ASX 200.

5-Year Financial Snapshot:

(Data Source: TradingView. Graphic Source: Pristine Gaze)

Over the past five years, AVA Risk Group Limited financial journey has shown consistency, with a meaningful recovery visible in 2024:

  • Revenue fell sharply from $46.13 million in 2020 to $18.62 million in 2022, then rebounded to $30.14 million in 2024. The recovery is supported by a 14% increase in total sales order intake, strong backlog ($8.5 million), and segment-wise growth—Access (up 38%) and Illuminate (up 5%)—alongside key partnerships with Telstra and dormakaba.
  • Operating cash flow showed a significant recovery in 2024, improving by 75.48% to –$0.54 million from –$2.18 million in 2023. While still negative, this trend suggests stabilisation following prior declines. The 2024 improvement aligns with stabilised costs and revenue momentum noted in H1’2025 with $1.07 million inflow, reflecting restructuring benefits and backlog conversion.

Relative Strength Index (RSI) Analysis:


Hourly Time-Frame (HTF)

(Graphic Source: TradingView)

Healius has demonstrated a marked improvement in

The RSI on the hourly time frame (HTF) has recently rebounded from oversold territory near the 30 level, indicating a shift in market sentiment. This slow but steady upward momentum now points toward the threshold of bullish zones, typically around the 50–60 mark, which often precedes stronger upward price action.


Daily Time-Frame (DTF)

(Graphic Source: TradingView)

The security’s RSI is currently positioned at 32 on the daily time frame (DTF), hovering just above oversold territory. This level, coupled with signs of waning selling pressure, suggests that the downside momentum is tapering off. Such conditions often precede a potential trend reversal, particularly when accompanied by stabilizing price action or supportive volume patterns. While confirmation is still needed, the current RSI behavior points toward the early stages of a base formation, encouraging a cautiously optimistic outlook for a short-term rebound.

Support & Resistance Analysis:

(Graphic Source: TradingView) Ava Risk Group Limited (ASX: AVA) Daily Time-Frame (DTF) Chart.

While the security may face some residual downside correction, the risk appears constrained, with technical support anticipated near the $0.084 level. This support zone may act as a stabilizing base in the short term. Additionally, the next major resistance level is situated around $0.11, indicating a relatively wide price gap. This dynamic establishes a favourable risk–reward profile for investors, as the potential upside notably outweighs the limited downside risk at current price levels.

Bollinger Bands Analysis:

(Graphic Source: TradingView) Ava Risk Group Limited (ASX: AVA) Daily Time-Frame (DTF) Chart.

The security has recently breached its lower Bollinger Bands, indicating the potential for a near-term trend reversal. This technical signal suggests a possible retracement toward its short-term simple moving average (SMA) near the $0.10 level. Should this recovery continue, there remains considerable scope for additional upside momentum, with the upper Bollinger Band around $0.12 serving as a potential short-term target.

Analyst’s Take:

AVA Risk Group is showing clear signs of operational and financial improvement, with strong revenue growth and a shift back to profitability. The business has benefitted from a more efficient cost structure and improved execution across its core segments. An increase in recurring revenue and a healthy order backlog point to strengthening customer relationships and growing demand for its security and sensing solutions. The company is expanding its reach across multiple industries and geographies through strategic partnerships and a scalable commercial model. This broader market presence, supported by a robust sales pipeline, positions AVA well for continued growth over the coming periods. Ongoing investment in product development and innovation enhances its ability to address evolving customer needs and industry trends. With stable financials and a clear focus on execution, the outlook remains constructive. The current RSI of 37.78 suggests the stock is nearing oversold levels, potentially offering a short-term opportunity.

As per Pristine Gaze, you may consider a “Buy” on “Ava Risk Group Limited” at the closing price of “$0.086” (As of 23 July 2025).

 

*All currency figures are in Australian Dollars unless stated otherwise.

*All data sourced from Company Reports and TradingView.

Disclaimer

The reports provided by Pristine Gaze are designed to deliver general financial insights, including stock and sector market analysis and investment commentary. These reports aim to support informed decision-making but are strictly intended for informational purposes. They do not constitute personalized financial advice and should not be relied upon as such. The information provided does not take into account individual investment objectives, financial circumstances, or specific needs.

General Advice Warning: The insights and recommendations offered in Pristine Gaze reports are of a general nature and are not tailored to any individual investor’s circumstances. Investment decisions are highly personal and depend on many factors, including but not limited to financial goals, risk tolerance, and current financial standing. We strongly advise consulting a qualified financial advisor who can evaluate your unique situation and provide professional guidance tailored to your needs before acting on any information contained in these reports.

Past Performance: Historical data, including past performance metrics of securities or markets mentioned in these reports, should not be regarded as an accurate indicator of future results. The financial markets are subject to significant variability, and past success does not guarantee similar outcomes in the future. It is essential to recognize that external factors, including but not limited to economic conditions, regulatory changes, and market dynamics, can greatly influence future performance and results.

Forward-Looking Statements: Certain projections and forecasts presented in Pristine Gaze reports may include forward-looking statements based on assumptions and expectations about future market conditions. These statements are speculative and inherently uncertain, as they depend on variables that may not materialize as anticipated. Factors such as economic conditions, market trends, policy changes, and unforeseen events can significantly impact these projections. Investors should approach forward-looking statements with caution and recognize the associated risks.

Data Accuracy: All financial data, metrics, and projections contained in our reports are derived from publicly available company filings, credible industry reports, and verified sources. While Pristine Gaze endeavors to ensure the accuracy, timeliness, and reliability of the information provided, we cannot guarantee its completeness or precision. Market conditions and company policies may evolve, leading to changes in the relevance of the data presented. The content of our reports may be updated or modified without prior notice.

Technical Analysis: Reports may include discussions of technical indicators, such as Relative Strength Index (RSI), Bollinger Bands, or moving averages. These indicators are tools used to analyze market trends but are inherently speculative and subject to interpretation. They do not provide definitive predictions about future price movements and should not be relied upon as sole determinants of investment decisions. Investors should combine technical analysis with other forms of research and risk assessment.

Dividend Yield: References to dividend payments or yields are based on historical data and the current financial policies of the companies discussed. Dividends are not guaranteed and may fluctuate depending on the financial performance of the company, market conditions, and regulatory requirements. Investors should consider these variables and the potential for dividend changes when evaluating dividend-paying securities.

Liability Disclaimer: Pristine Gaze, along with its directors, employees, associates, and affiliates, assumes no responsibility or liability for any losses or damages incurred due to reliance on the information or recommendations contained in our reports. This disclaimer applies to all forms of losses, including but not limited to direct, indirect, incidental, or consequential losses. Investors are hereby advised to conduct their independent research and seek professional advice before making investment decisions.

Third-Party Data and Links: some reports may reference external data, include hyperlinks to third-party websites, or incorporate information from other sources. While we aim to use credible and reliable references, Pristine Gaze does not endorse or take responsibility for the accuracy or reliability of external content. Users are advised to evaluate third-party information critically and acknowledge the risks of using such data.

Intellectual Property: All content within Pristine Gaze reports, including but not limited to text, graphics, designs, methodologies, and analyses, is the exclusive intellectual property of Pristine Gaze Pty Ltd. This content is protected under Australian and international copyright and trademark laws. Unauthorized reproduction, modification, or distribution of any part of the content without prior written consent from Pristine Gaze is strictly prohibited. Legal action may be pursued in the case of infringement.

Terms and Policies: For additional information regarding the terms and conditions of our services, our approach to data privacy, and the scope of our financial advice, please refer to our Terms and Conditions, Privacy Policy, and Financial Services Guide, which are available on our official website. 

Healius Limited (ASX: HLS)

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Healius Limited

ASX:
HLS

Healius Ltd. engages in the provision of healthcare technology solutions. It operates through the following segments: Pathology, Imaging, and Other. The Pathology segment provides pathology services. The Imaging segment focuses on imaging services from stand-alone imaging sites, hospitals, and medical centers. The Other segment consists of corporate functions. The company was founded by Edmund Gregory Thomas Bateman in 1985 and is headquartered in St. Leonards, Australia.

Stock Performance Profile:

(Source: TradingView) One-Year Performance Profile of HLS compared to ASX 200.

5-Year Financial Snapshot:

(Graphic Source: TradingView)

Healius Limited is currently undergoing a significant strategic transformation, reflected in its widening net loss of $654 million in FY24, up from $374 million in FY23. The loss was primarily driven by asset impairments and the divestment of Lumus Diagnostics, a move aligned with the company’s ongoing restructuring efforts. Despite the headline loss, the divestment contributed to a $210 million reduction in total liabilities, resulting in a more streamlined balance sheet. Revenue held steady at $1.75 billion, albeit below FY22 levels. Notably, the asset turnover ratio improved to 0.53 from 0.44, indicating enhanced operational efficiency. Although revenue declined in the first half of FY25, early signs of recovery are emerging through targeted cost-reduction initiatives and the reallocation of capital toward core operations.

Relative Strength Index (RSI) Analysis:


Hourly Time-Frame (HTF)

(Graphic Source: TradingView)

Healius has demonstrated a marked improvement in market buying sentiment over the past few weeks, most clearly reflected in the recovery of its Relative Strength Index (RSI), which has climbed from oversold territory around 28 in early July 2025 to 51 currently. This shift signals the emergence of bullish momentum and indicates a potential change in trend. With the RSI still in neutral territory, there remains considerable room for further upside, suggesting the stock may continue to gain strength in the near term if positive sentiment persists.


Daily Time-Frame (DTF)

(Graphic Source: TradingView)

On the daily timeframe, the security has recently rebounded from oversold territory, with the Relative Strength Index (RSI) currently at 34. This positioning indicates that downside risk is relatively limited at present, providing a level of support for investors. At the same time, the low RSI suggests ample room for further upward movement, highlighting the potential for a meaningful recovery should positive momentum continue to build.

Support & Resistance Analysis:

(Graphic Source: TradingView) Healius Limited (ASX: HLS) Daily Time-Frame (DTF) Chart.

The security is currently trading near a critical support zone at $0.69, which serves as a strong technical floor and significantly limits downside risk by reducing the likelihood of sustained selling pressure. This support level reinforces investor confidence and offers a degree of price stability. Furthermore, the next major resistance is located considerably higher around $1.22, creating substantial room for potential upside. This wide gap between support and resistance levels presents an attractive risk-to-reward profile, making the security compelling for investors seeking asymmetric return potential.

Bollinger Bands Analysis:

(Graphic Source: TradingView) Healius Limited (ASX: HLS) Daily Time-Frame (DTF) Chart.

The security has recently rebounded from its lower Bollinger Band and is currently retracing toward its simple moving averages near $0.766, indicating the potential for immediate short-term upside. This upward movement suggests improving momentum, and given the current trajectory, there is a reasonable likelihood that the stock could test its upper Bollinger Band around $0.83. This scenario reflects a favorable technical setup, with room for further gains if positive sentiment continues.

Analyst’s Take:

Healius Limited is navigating a transitional phase, implementing strategic initiatives aimed at strengthening its core operations and driving long-term performance improvements. Although revenue has remained stable, the company reported a wider net loss, largely attributable to asset impairments and the financial impact of recent divestments. In response, Healius has launched its T27 transformation plan, which focuses on revenue growth through the introduction of new products designed to expand service offerings and enhance competitiveness. The plan also includes the full elimination of standard costs by FY26, a move expected to significantly improve profitability. Additionally, the company is exploring expansion into high-potential areas such as genomics and veterinary diagnostics, which could support future growth. While external challenges such as regulatory shifts and inflationary pressures persist, Healius’ reinvestment strategy and improving operational efficiency provide a solid foundation for recovery. For long-term investors, the current valuation may present a compelling opportunity with meaningful turnaround potential.

As per Pristine Gaze, you may consider a “Buy” on “Healius Limited” at the closing price of “$0.74” (As of 9 July 2025).

 

*All currency figures are in Australian Dollars unless stated otherwise.

*All data sourced from Company Reports and TradingView.

Disclaimer

The reports provided by Pristine Gaze are designed to deliver general financial insights, including stock and sector market analysis and investment commentary. These reports aim to support informed decision-making but are strictly intended for informational purposes. They do not constitute personalized financial advice and should not be relied upon as such. The information provided does not take into account individual investment objectives, financial circumstances, or specific needs.

General Advice Warning: The insights and recommendations offered in Pristine Gaze reports are of a general nature and are not tailored to any individual investor’s circumstances. Investment decisions are highly personal and depend on many factors, including but not limited to financial goals, risk tolerance, and current financial standing. We strongly advise consulting a qualified financial advisor who can evaluate your unique situation and provide professional guidance tailored to your needs before acting on any information contained in these reports.

Past Performance: Historical data, including past performance metrics of securities or markets mentioned in these reports, should not be regarded as an accurate indicator of future results. The financial markets are subject to significant variability, and past success does not guarantee similar outcomes in the future. It is essential to recognize that external factors, including but not limited to economic conditions, regulatory changes, and market dynamics, can greatly influence future performance and results.

Forward-Looking Statements: Certain projections and forecasts presented in Pristine Gaze reports may include forward-looking statements based on assumptions and expectations about future market conditions. These statements are speculative and inherently uncertain, as they depend on variables that may not materialize as anticipated. Factors such as economic conditions, market trends, policy changes, and unforeseen events can significantly impact these projections. Investors should approach forward-looking statements with caution and recognize the associated risks.

Data Accuracy: All financial data, metrics, and projections contained in our reports are derived from publicly available company filings, credible industry reports, and verified sources. While Pristine Gaze endeavors to ensure the accuracy, timeliness, and reliability of the information provided, we cannot guarantee its completeness or precision. Market conditions and company policies may evolve, leading to changes in the relevance of the data presented. The content of our reports may be updated or modified without prior notice.

Technical Analysis: Reports may include discussions of technical indicators, such as Relative Strength Index (RSI), Bollinger Bands, or moving averages. These indicators are tools used to analyze market trends but are inherently speculative and subject to interpretation. They do not provide definitive predictions about future price movements and should not be relied upon as sole determinants of investment decisions. Investors should combine technical analysis with other forms of research and risk assessment.

Dividend Yield: References to dividend payments or yields are based on historical data and the current financial policies of the companies discussed. Dividends are not guaranteed and may fluctuate depending on the financial performance of the company, market conditions, and regulatory requirements. Investors should consider these variables and the potential for dividend changes when evaluating dividend-paying securities.

Liability Disclaimer: Pristine Gaze, along with its directors, employees, associates, and affiliates, assumes no responsibility or liability for any losses or damages incurred due to reliance on the information or recommendations contained in our reports. This disclaimer applies to all forms of losses, including but not limited to direct, indirect, incidental, or consequential losses. Investors are hereby advised to conduct their independent research and seek professional advice before making investment decisions.

Third-Party Data and Links: some reports may reference external data, include hyperlinks to third-party websites, or incorporate information from other sources. While we aim to use credible and reliable references, Pristine Gaze does not endorse or take responsibility for the accuracy or reliability of external content. Users are advised to evaluate third-party information critically and acknowledge the risks of using such data.

Intellectual Property: All content within Pristine Gaze reports, including but not limited to text, graphics, designs, methodologies, and analyses, is the exclusive intellectual property of Pristine Gaze Pty Ltd. This content is protected under Australian and international copyright and trademark laws. Unauthorized reproduction, modification, or distribution of any part of the content without prior written consent from Pristine Gaze is strictly prohibited. Legal action may be pursued in the case of infringement.

Terms and Policies: For additional information regarding the terms and conditions of our services, our approach to data privacy, and the scope of our financial advice, please refer to our Terms and Conditions, Privacy Policy, and Financial Services Guide, which are available on our official website. 

Genetic Signatures Limited (ASX: GSS)

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Genetic Signatures Limited

ASX:
GSS

Genetic Signatures Ltd. is a research company, which engages in the identification and commercialization of individual genetic signatures for the diagnosis of infectious diseases. It is also involved in the sale of associated products into the diagnostic and research marketplaces. Its products include the treatment for gastrointestinal infections, respiratory, sexual health, anti-microbial resistance, meningitis, and tropical disease. It operates in the following geographical segments: Asia Pacific, Europe, Middle East, and Africa (EMEA), and Americas. The company was founded by Robert J. Birrell, Christopher M. Abbott, and Geoffrey Grigg on February 15, 2001 and is headquartered in Newtown, Australia.

Stock Performance Profile:

(Source: TradingView) One-Year Performance Profile of GSS compared to ASX 200.

5-Year Financial Snapshot:

(Graphic Source: TradingView)

Genetic Signatures is demonstrating a clear financial recovery following the trough in H1 FY24, when revenue declined to $3.6 million. In H1 FY25, revenue rebounded strongly to $8.5 million—reflecting a 135% increase—driven by growth across both domestic and international markets. While still below the H1 FY23 peak of $10.4 million, the upward trajectory signals a return to pre-downturn levels. Additionally, the inventory turnover ratio improved to 3.77x, indicating enhanced operational discipline and stronger sales velocity.

Relative Strength Index (RSI) Analysis:


Hourly Time-Frame (HTF)

(Graphic Source: TradingView)

On the hourly timeframe, the security has demonstrated a notable recovery in market sentiment, with the Relative Strength Index (RSI) rebounding from deeply oversold levels of 19 to its current reading of 41. This upward movement in RSI suggests a shift in momentum and indicates the potential emergence of bullish sentiment, positioning the security for a possible short-term upswing.


Daily Time-Frame (DTF)

(Graphic Source: TradingView)

On the daily timeframe, the security remains near oversold territory with a Relative Strength Index (RSI) of 33. This positioning not only limits further downside risk but also enhances the potential for a technical rebound. The low RSI level suggests that the security may be undervalued in the short term, creating favorable conditions for a recovery and offering scope for considerable upside.

Support & Resistance Analysis:

(Graphic Source: TradingView) Genetic Signatures Limited (ASX: GSS) Daily Time-Frame (DTF) Chart.

The security is currently positioned near a strong support level around $0.365, which has historically provided price stability and now signals the potential for a recovery. This proximity to support effectively limits downside risk for investors. In contrast, the nearest significant resistance lies further away at approximately $0.485, highlighting a favorable risk-reward profile.

Bollinger Bands Analysis:

(Graphic Source: TradingView) Genetic Signatures Limited (ASX: GSS) Daily Time-Frame (DTF) Chart.

The security is currently rebounding from its lower Bollinger Band, suggesting the potential for a short-term recovery as it moves toward its simple moving averages. This price action indicates improving momentum following a period of downward pressure. Additionally, the wide gap between the upper and lower Bollinger Bands reflects healthy market volatility, which could support meaningful short-term price movement and present opportunities for active investors.

Analyst’s Take:

Genetic Signatures Limited is showing signs of operational recovery, supported by improving sales momentum and enhanced inventory efficiency. The company appears to be regaining traction after a challenging period, with recent trends suggesting better commercial execution and more efficient resource utilization. Despite ongoing bottom-line pressures, the narrowing of losses points toward progress in cost management and strategic focus. Technically stock nears oversold levels, signaling potential consolidation and rebound phase. Overall, with improving fundamentals and signs of technical stabilization, Genetic Signatures appears well-positioned to benefit from renewed investor confidence and deliver meaningful upside over the short-term.

As per Pristine Gaze, you may consider a “Buy” on “Genetic Signatures Limited” at the closing price of “$0.37” (As of 25 June 2025).

 

*All currency figures are in Australian Dollars unless stated otherwise.

*All data sourced from Company Reports and TradingView.

Disclaimer

The reports provided by Pristine Gaze are designed to deliver general financial insights, including stock and sector market analysis and investment commentary. These reports aim to support informed decision-making but are strictly intended for informational purposes. They do not constitute personalized financial advice and should not be relied upon as such. The information provided does not take into account individual investment objectives, financial circumstances, or specific needs.

General Advice Warning: The insights and recommendations offered in Pristine Gaze reports are of a general nature and are not tailored to any individual investor’s circumstances. Investment decisions are highly personal and depend on many factors, including but not limited to financial goals, risk tolerance, and current financial standing. We strongly advise consulting a qualified financial advisor who can evaluate your unique situation and provide professional guidance tailored to your needs before acting on any information contained in these reports.

Past Performance: Historical data, including past performance metrics of securities or markets mentioned in these reports, should not be regarded as an accurate indicator of future results. The financial markets are subject to significant variability, and past success does not guarantee similar outcomes in the future. It is essential to recognize that external factors, including but not limited to economic conditions, regulatory changes, and market dynamics, can greatly influence future performance and results.

Forward-Looking Statements: Certain projections and forecasts presented in Pristine Gaze reports may include forward-looking statements based on assumptions and expectations about future market conditions. These statements are speculative and inherently uncertain, as they depend on variables that may not materialize as anticipated. Factors such as economic conditions, market trends, policy changes, and unforeseen events can significantly impact these projections. Investors should approach forward-looking statements with caution and recognize the associated risks.

Data Accuracy: All financial data, metrics, and projections contained in our reports are derived from publicly available company filings, credible industry reports, and verified sources. While Pristine Gaze endeavors to ensure the accuracy, timeliness, and reliability of the information provided, we cannot guarantee its completeness or precision. Market conditions and company policies may evolve, leading to changes in the relevance of the data presented. The content of our reports may be updated or modified without prior notice.

Technical Analysis: Reports may include discussions of technical indicators, such as Relative Strength Index (RSI), Bollinger Bands, or moving averages. These indicators are tools used to analyze market trends but are inherently speculative and subject to interpretation. They do not provide definitive predictions about future price movements and should not be relied upon as sole determinants of investment decisions. Investors should combine technical analysis with other forms of research and risk assessment.

Dividend Yield: References to dividend payments or yields are based on historical data and the current financial policies of the companies discussed. Dividends are not guaranteed and may fluctuate depending on the financial performance of the company, market conditions, and regulatory requirements. Investors should consider these variables and the potential for dividend changes when evaluating dividend-paying securities.

Liability Disclaimer: Pristine Gaze, along with its directors, employees, associates, and affiliates, assumes no responsibility or liability for any losses or damages incurred due to reliance on the information or recommendations contained in our reports. This disclaimer applies to all forms of losses, including but not limited to direct, indirect, incidental, or consequential losses. Investors are hereby advised to conduct their independent research and seek professional advice before making investment decisions.

Third-Party Data and Links: some reports may reference external data, include hyperlinks to third-party websites, or incorporate information from other sources. While we aim to use credible and reliable references, Pristine Gaze does not endorse or take responsibility for the accuracy or reliability of external content. Users are advised to evaluate third-party information critically and acknowledge the risks of using such data.

Intellectual Property: All content within Pristine Gaze reports, including but not limited to text, graphics, designs, methodologies, and analyses, is the exclusive intellectual property of Pristine Gaze Pty Ltd. This content is protected under Australian and international copyright and trademark laws. Unauthorized reproduction, modification, or distribution of any part of the content without prior written consent from Pristine Gaze is strictly prohibited. Legal action may be pursued in the case of infringement.

Terms and Policies: For additional information regarding the terms and conditions of our services, our approach to data privacy, and the scope of our financial advice, please refer to our Terms and Conditions, Privacy Policy, and Financial Services Guide, which are available on our official website. 

Propel Funeral Partners Limited (ASX: PFP)

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Propel Funeral Partners Limited

ASX:
PFP

Propel Funeral Partners Ltd. engages in the provision of death care related services. It operates through the following geographical segments: Australian Operations and New Zealand Operations. The company was founded by Fraser Henderson, Peter Dowding and Albin Kurti in 2012 and is headquartered in Sydney, Australia.

Stock Performance Profile:

(Source: TradingView) One-Year Performance Profile of PFP compared to ASX 200.

5-Year Financial Snapshot:

(Graphic Source: TradingView)

Propel Funeral has demonstrated substantial financial growth over the past five years, with revenue increasing from $110.63 million in 2020 to $208.7 million in 2024. During the same period, net income rose from $10.62 million to $17.81 million, reflecting a consistent improvement in profitability. This performance underscores the company’s strong operational execution and long-term scalability, as it continues to expand its presence and optimize its earnings profile within the funeral services industry.

Relative Strength Index (RSI) Analysis:


Hourly Time-Frame (HTF)

(Graphic Source: TradingView)

The company’s 14-day Relative Strength Index (RSI) on the hourly timeframe has reached 49.31, indicating gradually strengthening buying momentum. This level places the security on the cusp of entering bullish territory, suggesting a potential short-term upside as market sentiment continues to improve.


Daily Time-Frame (DTF)

(Graphic Source: TradingView)

The security’s 14-day Relative Strength Index (RSI) on the daily chart is rebounding from oversold territory, with momentum beginning to improve noticeably in early June 2025. This recovery suggests a potential for continued upward movement, supported by stabilizing technical indicators. At the same time, downside risk appears limited in the near term, reinforcing a more favorable risk-reward outlook for the security.

Support & Resistance Analysis:

(Graphic Source: TradingView) Propel Funeral Partners Limited (ASX: PFP) Daily Time-Frame (DTF) Chart.

The security is currently establishing strong support around the $4.29 level, which helps to mitigate near-term downside risk. With the next immediate resistance positioned at approximately $4.71—relatively distant from current levels—there is a notable opportunity for short-term upside. Furthermore, a key resistance zone around $5.30 suggests additional room for potential gains should the security sustain its upward momentum and break through interim resistance levels.

Bollinger Bands Analysis:

(Graphic Source: TradingView) Propel Funeral Partners Limited (ASX: PFP) Daily Time-Frame (DTF) Chart.

The security recently breached its lower Bollinger Band, a potential signal of a short-term reversal, especially given that it has not retested this lower band since. This suggests improving momentum and stabilizing price action. Moreover, the current wide spread between the upper and lower Bollinger Bands reflects healthy volatility, which could create favorable trading conditions and opportunities for investors seeking upside in a recovering trend.

Analyst’s Take:

Despite a recent decline in its stock price, Propel Funeral continues to demonstrate a strong track record of financial growth, with its latest first-half results indicating both continuity and acceleration of its long-term upward trend. The company’s current price-to-sales (P/S) ratio of 2.8x, compared to its historical average of around 3.5x, suggests a potential undervaluation relative to its past performance. Operating within the increasingly in-demand death care services sector and supported by demographic trends such as a growing elderly population, Propel Funeral is well-positioned for continued expansion and sustained growth in the years ahead.

As per Pristine Gaze, you may consider a “Buy” on “Propel Funeral Partners Limited” at the closing price of “$4.45” (As of 04 June 2025).

*All currency figures are in Australian Dollars unless stated otherwise.

*All data sourced from Company Reports and TradingView.

Disclaimer

The reports provided by Pristine Gaze are designed to deliver general financial insights, including stock and sector market analysis and investment commentary. These reports aim to support informed decision-making but are strictly intended for informational purposes. They do not constitute personalized financial advice and should not be relied upon as such. The information provided does not take into account individual investment objectives, financial circumstances, or specific needs.

General Advice Warning: The insights and recommendations offered in Pristine Gaze reports are of a general nature and are not tailored to any individual investor’s circumstances. Investment decisions are highly personal and depend on many factors, including but not limited to financial goals, risk tolerance, and current financial standing. We strongly advise consulting a qualified financial advisor who can evaluate your unique situation and provide professional guidance tailored to your needs before acting on any information contained in these reports.

Past Performance: Historical data, including past performance metrics of securities or markets mentioned in these reports, should not be regarded as an accurate indicator of future results. The financial markets are subject to significant variability, and past success does not guarantee similar outcomes in the future. It is essential to recognize that external factors, including but not limited to economic conditions, regulatory changes, and market dynamics, can greatly influence future performance and results.

Forward-Looking Statements: Certain projections and forecasts presented in Pristine Gaze reports may include forward-looking statements based on assumptions and expectations about future market conditions. These statements are speculative and inherently uncertain, as they depend on variables that may not materialize as anticipated. Factors such as economic conditions, market trends, policy changes, and unforeseen events can significantly impact these projections. Investors should approach forward-looking statements with caution and recognize the associated risks.

Data Accuracy: All financial data, metrics, and projections contained in our reports are derived from publicly available company filings, credible industry reports, and verified sources. While Pristine Gaze endeavors to ensure the accuracy, timeliness, and reliability of the information provided, we cannot guarantee its completeness or precision. Market conditions and company policies may evolve, leading to changes in the relevance of the data presented. The content of our reports may be updated or modified without prior notice.

Technical Analysis: Reports may include discussions of technical indicators, such as Relative Strength Index (RSI), Bollinger Bands, or moving averages. These indicators are tools used to analyze market trends but are inherently speculative and subject to interpretation. They do not provide definitive predictions about future price movements and should not be relied upon as sole determinants of investment decisions. Investors should combine technical analysis with other forms of research and risk assessment.

Dividend Yield: References to dividend payments or yields are based on historical data and the current financial policies of the companies discussed. Dividends are not guaranteed and may fluctuate depending on the financial performance of the company, market conditions, and regulatory requirements. Investors should consider these variables and the potential for dividend changes when evaluating dividend-paying securities.

Liability Disclaimer: Pristine Gaze, along with its directors, employees, associates, and affiliates, assumes no responsibility or liability for any losses or damages incurred due to reliance on the information or recommendations contained in our reports. This disclaimer applies to all forms of losses, including but not limited to direct, indirect, incidental, or consequential losses. Investors are hereby advised to conduct their independent research and seek professional advice before making investment decisions.

Third-Party Data and Links: some reports may reference external data, include hyperlinks to third-party websites, or incorporate information from other sources. While we aim to use credible and reliable references, Pristine Gaze does not endorse or take responsibility for the accuracy or reliability of external content. Users are advised to evaluate third-party information critically and acknowledge the risks of using such data.

Intellectual Property: All content within Pristine Gaze reports, including but not limited to text, graphics, designs, methodologies, and analyses, is the exclusive intellectual property of Pristine Gaze Pty Ltd. This content is protected under Australian and international copyright and trademark laws. Unauthorized reproduction, modification, or distribution of any part of the content without prior written consent from Pristine Gaze is strictly prohibited. Legal action may be pursued in the case of infringement.

Terms and Policies: For additional information regarding the terms and conditions of our services, our approach to data privacy, and the scope of our financial advice, please refer to our Terms and Conditions, Privacy Policy, and Financial Services Guide, which are available on our official website.